next target, page-17

One factor that contributed to the sell off (consequent to the above mentioned issues) was the published Stop Loss of the newsletter, which saw all those subscribers rush for the exit.

Since PRR is no longer covered and presumably all those wood ducks have flown the coop, it's one less consideration for any possible downward pressure.

Regarding the Phase iii trial recruitment, judging by the mentions in a number of periodicals and the Ovaraian Cancer Association, clearly the preparatory work is underway. A formal announcement of the recruitment process could not be too far away.